LMNLI called Liminal BioSciences Inc (NASDAQ:LMNL) recently at $4.40 as a potential big runner due to the PDUFA catalyst. On Friday, just a few minutes before the close, the stock was halted and the U.S. Food & Drug Administration (FDA) announced the approval of Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA approved therapy for this rare genetic disorder. The stock closed the after-hours trading gaining more than 55% with 8.2M shares traded. Congratulations to those who bought and profited on LMNL in after-hours, further gains are by no means guaranteed and it never hurts to lock profits in after being up almost 70%. Let's see that $7 break on Monday and see if the stock wants more gains, consolidation, or a pull back.
